Earnings Call Summary | Virios Therapeutics(VIRI.US) Q1 2024 Earnings Conference
Earnings Call Summary | Virios Therapeutics(VIRI.US) Q1 2024 Earnings Conference
The following is a summary of the Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript:
以下是Virios Therapeutics, Inc.(VIRI)2024年第一季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Virios Therapeutics reported a decrease in research and development expenses, which were $0.3 million for Q1 2024 compared to $0.5 million for Q1 2023.
The company also saw a slight decrease in general and administrative expenses, going from $1.1 million in Q1 2023 to $1 million in Q1 2024.
A reduction in net loss was reported, with the Q1 2024 figure being $1.3 million compared to $1.5 million in Q1 2023.
As of March 31, 2024, the company held cash totaling $2.4 million, down from $3.3 million recorded at the end of 2023.
Virios Therapeutics報告稱,研發費用有所減少,2024年第一季度爲30萬美元,而2023年第一季度爲50萬美元。
該公司的一般和管理費用也略有下降,從2023年第一季度的110萬美元降至2024年第一季度的100萬美元。
據報道,淨虧損有所減少,2024年第一季度的數字爲130萬美元,而2023年第一季度爲150萬美元。
截至2024年3月31日,該公司持有的現金總額爲240萬美元,低於2023年底的330萬美元。
Business Progress:
業務進展:
The company has achieved 50% enrollment in the ongoing Bateman Horne Center Long-COVID Phase 2 study with no serious adverse events so far.
Research suggests that Virios' therapeutic targets, herpesviruses, may trigger Long-COVID in a percentage of sufferers.
The company expects top-line results from this study in the second half of 2024.
Virios Therapeutics' global patent for IMC-2, meant for the antiviral treatment of Long-COVID and Alzheimer's disease, has recently been published.
For the treatment of fibromyalgia, the firm intends to partner up to proceed with Phase 3 development of their second development candidate IMC-1.
Virios is considering different possibilities to enhance shareholder value, which may include strategic partnerships, collaborations, or other types of transactions.
該公司在正在進行的貝特曼·霍恩中心長期COVID二期研究中已有50%的入學率,到目前爲止沒有發生嚴重的不良事件。
研究表明,Virios的治療靶點皰疹病毒可能會在一定比例的患者中觸發Long-COVID。
該公司預計,這項研究將在2024年下半年得出最佳結果。
Virios Therapeutics的 IMC-2 全球專利最近已公佈,該專利旨在抗病毒治療長冠狀病毒和阿爾茨海默氏病。
爲了治療纖維肌痛,該公司打算合作,繼續進行第二種開發候選藥物 IMC-1 的第三階段開發。
Virios正在考慮提高股東價值的不同可能性,其中可能包括戰略伙伴關係、合作或其他類型的交易。
More details: Virios Therapeutics IR
更多詳情: Virios 治療公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。